With the market in general, currently yes although a 300M cap ain't bad for OTC. With the Big Pharma agreements behind the scenes, no. With the leading trial centers, no. With the pipeline and platforms, no. I sense the former is rapidly changing to a no also and quickly....................
Market Data 
Markets 
AI
